Emergen Research has recently published a new report on the Global Liquid Biopsy market that offers key insights about the regional and global scope of the Liquid Biopsy market. It offers key details about the recent product launches, technological advancements, supply and demand ratio, and regulatory framework. The report also offers details about market size, market share, revenue growth, and CAGR during the forecast period of 2023-2032.
The global liquid biopsy market size is expected to reach USD 7,645.0 Million in 2030 and register a revenue CAGR of 20.3% over the forecast period, according to the latest analysis by Emergen Research. Rise in demand for early cancer detection is a key factor driving global liquid biopsy market revenue growth.
Liquid biopsy is a safe and popular procedure carried out during examination of cancer. The procedure is easy and minimally invasive, allows early detection and diagnosis of cancer, and helps in identification of cancer treatment. In addition, growing popularity of non-invasive techniques is driving private and public financing for research in the field of liquid biopsy, which allow medical professionals to discover various aspects of a tumor through a patient’s blood sample. It facilitates medical professionals to understand, which treatments are suitable for patients.
Development of liquid biopsy has led to a better understanding of molecular diagnostics of circulating tumor DNA. Increased adoption of liquid biopsy in cancer is due to its potential for non-invasive detection of targeted genomic alteration in correspondence to targeted therapy. Non-cancerous application of liquid biopsy includes diagnosis of heart attack and atherosclerosis. Advancement in next-generation sequencing for patients with advanced stages of cancer is driving market growth.
The report also offers key insights about top companies in the market along with a thorough SWOT analysis, Porter’s Five Forces analysis, and feasibility analysis to offer competitive edge to the readers. The report focuses on the recent trends, major challenges and opportunities, and limitations pertaining to the ongoing pandemic.
Get a sample of the report @ https://www.emergenresearch.com/request-sample/34
The report also discusses the key players involved in the market such as Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant Health, Inc., RainDance Technologies, Inc., Biocept, Inc., Qiagen N.V., Trovagene, Inc., and F. Hoffmann-La Roche Ltd and others as well as new entrants in the market. It focuses on the recent mergers & acquisitions, joint ventures, collaborations, partnerships, licensing agreements, brand promotions, and product launches, among others. The report also provides details about the company overview, business expansion plans, product portfolio, manufacturing and production capacity, global market position, financial status, and consumer base.
Key insights presented in the report:
- Market revenue shares by major business players, by type, by application, and market scope of global Liquid Biopsy market
- Sales revenue by key players and new entrants
- Competitive analysis of the key players including aspects such as company overview, product or services specification, vendors, and buyers.
- Recent mergers, acquisitions, product launches, recent investments, and joint ventures
- Regional analysis to provide insight to recent trends and opportunities
The competitive analysis also includes regional analysis of major geographical regions. The report covers regions such as North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The report also offers a country wise analysis to impart better understanding of the global Liquid Biopsy market with regards to market share, market size, production and consumption ratio, product launches and R&D activities, investment opportunities, and presence of key players in the region.
The report further segments the global Liquid Biopsy market on the basis of product types and applications and provides insights into key factors influencing the revenue growth of the segments.
- Product Outlook (Revenue, USD Billion; 2018–2028)
- Assays Kits
- Instruments
- Services
- Circulating Biomarkers Outlook (Revenue, USD Billion; 2018–2028)
- Circulating Tumor DNA (ctDNA)
- Circulating Tumor Cells (CTCs)
- Extracellular Vesicles (EVs)
- Cell-Free DNA (cfDNA)
- Other Circulating Biomarkers
- Sample Type Outlook (Revenue, USD Billion; 2018–2028)
- Blood Sample based
- Urine Sample based
- Other Bio Fluids based
The report focuses on current and future market growth, technological advancements, volume, raw materials, and profiles of the key companies involved in the market. The report provides valuable insights to the stakeholders, investors, product managers, marketing executives, and other industry professionals.
To know more about the report @ https://www.emergenresearch.com/industry-report/liquid-biopsy-market
Thank you for reading our report. Please get in touch with us if you have any query regarding the report or its customization. Our team will ensure the report is best suited to your needs.
